CR10997A - Metodo de tratamiento de canceres - Google Patents

Metodo de tratamiento de canceres

Info

Publication number
CR10997A
CR10997A CR10997A CR10997A CR10997A CR 10997 A CR10997 A CR 10997A CR 10997 A CR10997 A CR 10997A CR 10997 A CR10997 A CR 10997A CR 10997 A CR10997 A CR 10997A
Authority
CR
Costa Rica
Prior art keywords
treatment method
cancer treatment
dichichi
peptid
agonist
Prior art date
Application number
CR10997A
Other languages
English (en)
Spanish (es)
Inventor
Lynn Erickson-Miller Connie
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CR10997A publication Critical patent/CR10997A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR10997A 2007-02-16 2009-08-26 Metodo de tratamiento de canceres CR10997A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03

Publications (1)

Publication Number Publication Date
CR10997A true CR10997A (es) 2009-10-16

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10997A CR10997A (es) 2007-02-16 2009-08-26 Metodo de tratamiento de canceres

Country Status (28)

Country Link
US (2) US20100075928A1 (OSRAM)
EP (1) EP2124547B3 (OSRAM)
JP (1) JP5511391B2 (OSRAM)
KR (1) KR101447763B1 (OSRAM)
CN (1) CN101662937B (OSRAM)
AR (1) AR065348A1 (OSRAM)
AU (1) AU2008216106C1 (OSRAM)
BR (1) BRPI0807940B8 (OSRAM)
CA (1) CA2678358C (OSRAM)
CR (1) CR10997A (OSRAM)
DK (1) DK2124547T6 (OSRAM)
EA (1) EA017715B1 (OSRAM)
ES (1) ES2675070T7 (OSRAM)
FI (1) FI2124547T4 (OSRAM)
HU (1) HUE038563T2 (OSRAM)
IL (2) IL200319A (OSRAM)
MA (1) MA31202B1 (OSRAM)
MX (1) MX2009008822A (OSRAM)
NZ (1) NZ579068A (OSRAM)
PE (1) PE20081784A1 (OSRAM)
PL (1) PL2124547T5 (OSRAM)
PT (1) PT2124547T (OSRAM)
SI (1) SI2124547T2 (OSRAM)
TR (1) TR201809010T4 (OSRAM)
TW (1) TW200906393A (OSRAM)
UY (1) UY30915A1 (OSRAM)
WO (1) WO2008101141A2 (OSRAM)
ZA (1) ZA200905532B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EA022915B1 (ru) * 2007-10-09 2016-03-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома
JP2012528184A (ja) 2009-05-29 2012-11-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチンアゴニスト化合物の投与の方法
CN103079551A (zh) * 2010-09-01 2013-05-01 诺华有限公司 Hdac抑制剂与血小板减少症药物的组合
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
IL262746B (en) * 2016-05-06 2022-09-01 Taris Biomedical Llc A method for treating urothelial cancer in the lower system
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
WO2001007423A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
CA2390095C (en) * 1999-11-10 2013-01-08 M. Rigdon Lentz Method and system to remove cytokine inhibitor in patients
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AU2001260661A1 (en) * 2000-05-30 2001-12-11 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
EP1284997B1 (en) * 2000-05-31 2005-04-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
JP4145655B2 (ja) 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物
WO2002062775A1 (en) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
EA007481B1 (ru) * 2001-09-24 2006-10-27 Тоск, Инк. Цисплатиновые составы пониженной токсичности и способы их применения
EP2314586B1 (en) * 2002-01-18 2016-09-14 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
TWI280128B (en) * 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
WO2004096154A2 (en) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
ATE486859T1 (de) 2004-10-25 2010-11-15 Ligand Pharm Inc Verbindungen modulierende thrombopoietinaktivität und verfahren
AU2006318527A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Incorporated Thrombopoietin activity modulating compounds and methods
BRPI0709286A2 (pt) 2006-03-15 2011-07-05 Ligand Pharm Inc processo de sìntese de compostos para modulção da atividade da trombopoietina

Also Published As

Publication number Publication date
EP2124547B3 (en) 2025-06-18
US20100075928A1 (en) 2010-03-25
AR065348A1 (es) 2009-06-03
SI2124547T1 (en) 2018-08-31
CN101662937A (zh) 2010-03-03
DK2124547T6 (da) 2025-09-01
IL200319A (en) 2015-05-31
AU2008216106C1 (en) 2025-11-13
SI2124547T2 (sl) 2025-07-31
IL238394B (en) 2018-05-31
DK2124547T3 (en) 2018-07-16
CA2678358A1 (en) 2008-08-21
BRPI0807940B1 (pt) 2020-10-27
WO2008101141A3 (en) 2008-10-16
HUE038563T2 (hu) 2018-10-29
AU2008216106B9 (en) 2013-09-05
PL2124547T3 (pl) 2018-08-31
PE20081784A1 (es) 2009-01-25
NZ579068A (en) 2012-05-25
EP2124547A4 (en) 2010-05-05
JP2010519221A (ja) 2010-06-03
EP2124547B2 (en) 2025-04-16
AU2008216106B2 (en) 2013-07-11
AU2008216106A1 (en) 2008-08-21
ES2675070T3 (es) 2018-07-06
TR201809010T4 (tr) 2018-07-23
CA2678358C (en) 2015-12-08
IL238394A0 (en) 2015-06-30
EP2124547A2 (en) 2009-12-02
BRPI0807940B8 (pt) 2021-05-25
BRPI0807940A2 (pt) 2013-07-30
MX2009008822A (es) 2009-08-28
JP5511391B2 (ja) 2014-06-04
WO2008101141A2 (en) 2008-08-21
CN101662937B (zh) 2014-03-12
PT2124547T (pt) 2018-07-04
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
EP2124547B1 (en) 2018-03-28
EA200970776A1 (ru) 2010-02-26
DK2124547T4 (da) 2025-08-04
KR101447763B1 (ko) 2014-10-07
UY30915A1 (es) 2008-09-02
FI2124547T4 (fi) 2025-07-29
ZA200905532B (en) 2010-04-28
TW200906393A (en) 2009-02-16
EA017715B1 (ru) 2013-02-28
IL200319A0 (en) 2010-04-29
ES2675070T7 (en) 2025-08-06
MA31202B1 (fr) 2010-02-01
PL2124547T5 (pl) 2025-08-04

Similar Documents

Publication Publication Date Title
CR10997A (es) Metodo de tratamiento de canceres
PH12020550741A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
GT200900182A (es) Inhibidores de la poli (adp-ribosa) polimerasa
CY1119251T1 (el) Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη
UY30492A1 (es) Anticuerpo antagonista para el tratamiento del cancer
UA103004C2 (ru) Гуманизированное антитело против cd79b и иммуноконъюгаты и способы применения
WO2012143499A3 (de) Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
MX359403B (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa.
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
CR11486A (es) Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
EA201300411A1 (ru) Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
CL2008001626A1 (es) Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
MY160041A (en) Compositions and methods for treating parasitic infections
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
CL2008002506A1 (es) Compuestos derivados de bencimidazol sustituido, procedimiento de preparacion, composicion farmaceutica, util en el tratamiento de enfermedades moduladas con antagonistas del receptor fxr, en particular para el tratamiento de los niveles incrementados de lipidos y/o colesterol, enfermedad aterosclerotica, diabetes, cancer, parkinson, alzheimer.
AR067730A1 (es) Anticuerpos y fragmentos de anticuerpos anti ephb4
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)